In males with non-metastatic prostate cancer, Gandaglia et al. revealed that the administration of GnRH agonists, but not orchidectomy, is still associated with a considerably higher risk of CAD, MI, and, especially SCD. Here, GNRH1 is linked to coronary artery disorder.